Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 16/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.67 |
| ▸ | DPP4 | P27487 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.67 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.67 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.67 |
| ▸ | GAPDH | P04406 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.67 |
| ▸ | STAT6 | P42226 | 1/20 | 0.67 |
| ▸ | PI4KA | P42356 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536023 | 0.90 | AHCY (0.79) | AHCYHIF1ATMEM97SIGMAR1ADORA2A | |
| SCHEMBL4150492 | 0.88 | AHCY (0.77) | AHCYHIF1ATMEM97SIGMAR1ADORA2A | |
| SCHEMBL4150498 | 0.88 | AHCY (0.77) | AHCYHIF1ATMEM97SIGMAR1ADORA2A | |
| SCHEMBL14304652 | 0.88 | AHCY (0.77) | AHCYHIF1ATMEM97SIGMAR1ADORA2A | |
| SCHEMBL9282755 | 0.88 | AHCY (0.77) | AHCYHIF1ATMEM97SIGMAR1ADORA2A | |
| SCHEMBL4776904 | 0.88 | AHCY (1.00) | AHCYHIF1ATMEM97SIGMAR1ADORA2A | |
| SCHEMBL3365586 | 0.87 | AHCY (0.60) | AHCYHIF1ATMEM97SIGMAR1ADORA2A | |
| SCHEMBL4868251 | 0.84 | AHCY (0.77) | AHCYHIF1ATMEM97SIGMAR1ADORA2A | |
| SCHEMBL4867325 | 0.84 | AHCY (0.77) | AHCYHIF1ATMEM97SIGMAR1ADORA2A | |
| SCHEMBL4867300 | 0.84 | AHCY (0.77) | AHCYHIF1ATMEM97SIGMAR1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200323895-A1 | Compounds, Compositions, and Methods for Treating And/Or Preventing Periodontal Disease | YALE UNIVERSITY | 2020-10-15 | — | — | US | claimed |
| WO-2010056795-A1 | NOVEL SYNTHETIC DINUCLEOSIDE POLYPHOSPHATE ANALOGS AND THEIR USE AS NEW THERAPEUTIC AND/OR DIAGNOSTIC MODALITIES | ZATA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-6713623-B2 | USEFUL AS INTERMEDIATES IN THE SYNTHESIS OF BIOLOGICALLY ACTIVE COMPOUNDS | PHARMASSET, LTD. | 2004-03-30 | — | — | US | claimed |
| EP-3716985-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING AND/OR PREVENTING PERIODONTAL DISEASE | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2020-10-07 | — | — | EP | disclosed |
| WO-2019104316-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING AND/OR PREVENTING PERIODONTAL DISEASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2010056795-A1 | NOVEL SYNTHETIC DINUCLEOSIDE POLYPHOSPHATE ANALOGS AND THEIR USE AS NEW THERAPEUTIC AND/OR DIAGNOSTIC MODALITIES | ZATA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-0934325-A4 | TETRAPHOSPHONATE BICYCLIC TRISANHYDRIDES | PHARMASSET LTD (US) | 2000-08-16 | — | — | EP | disclosed |
| EP-0934325-A1 | TETRAPHOSPHONATE BICYCLIC TRISANHYDRIDES | Pharmasset, Ltd. (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015563-A1 | TETRAPHOSPHONATE BICYCLIC TRISANHYDRIDES | PHARMASSET, LTD. (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323895-A1 | Compounds, Compositions, and Methods for Treating And/Or Preventing Periodontal Disease | ENPP1, ENPP3, PPA1 | AHCY 80/4885HIF1A 2121/4885TMEM97 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.